secwatch.observer — SEC 8-K summary
======================================

Issuer:     GeoVax Labs, Inc. (GOVX)
CIK:        0000832489
Form:       8-K
Filed at:   2023-03-24T23:59:59+00:00
Accession:  0001437749-23-007711
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GeoVax 2022 net loss $14.0M, cash $27.6M; clinical trials expand
----------------------------------------------------------------

- Net loss for 2022 was $14.0M, versus $18.6M in 2021; R&D expenses fell to $9.1M from $15.6M.
- Cash balance at Dec 31, 2022: $27.6M, up from $11.4M in 2021; raised $35.4M from equity and warrant exercises.
- Phase 1/2 trial of Gedeptin® for advanced head & neck cancer expanded to three NCI Cancer Centers.
- GEO-CM04S1 COVID-19 vaccine advancing in two Phase 2 trials; data show robust T cell and antibody responses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/832489/000143774923007711/0001437749-23-007711-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/832489/000143774923007711/govx20230323_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-007711

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer